TRH (Thyrotropin-releasing hormone)
Also known as: Glu-His-Pro-NH2 · thyrotropin-releasing factor · TRF · protirelin
The endogenous hypothalamic tripeptide that stimulates thyroid-stimulating hormone release, with distinctive research history in cognitive effects, arousal, mood modulation, and neuroprotective applications separated from the primary thyroid-axis pharmacology.
TRH (thyrotropin-releasing hormone) is the endogenous hypothalamic tripeptide with a distinctive research history in cognitive effects, arousal, and neuroprotection separated from thyroid-axis pharmacology.
Evidence tier: A — ≥1 RCT + meta-analysis or approved clinical use
- Category
- Cognitive Enhancement
- Half-life
- Very short plasma half-life (minutes)
Section 1
Overview
TRH (thyrotropin-releasing hormone) is the hypothalamic tripeptide (pyroglutamyl-histidyl-prolinamide) that stimulates thyroid-stimulating hormone (TSH) release from the anterior pituitary as the initiator of the hypothalamic-pituitary-thyroid axis. Its best-established clinical use has been as a diagnostic agent (protirelin) in the TRH test of pituitary-thyroid function, an approach that has largely been superseded by ultrasensitive TSH assays and is seldom employed now (Wikipedia, Thyrotropin-releasing hormone). Its cognitive-relevance emerges from a substantial research literature on effects on arousal, mood, cognitive performance, and neuroprotection that are separable from the primary thyroid-axis pharmacology.
The compound has been extensively characterised as a mood and arousal modulator, with reported antidepressant effects in some research contexts. The mechanism-of-action framework for these effects operates through central TRH receptor engagement on neuronal populations expressing the receptor, distinct from the peripheral pituitary-thyroid-axis pathway.
TRH's research applications include cognitive endpoint research, depression and mood disorder research, ALS and neurodegenerative disease research (where limited early clinical evaluation occurred), and general arousal-and-alertness research. It occupies a distinctive research-tool niche alongside the vasopressin-family and ACTH-fragment classical cognitive peptides.
Section 2
Discovery & History
- First isolated and characterised in 1969 by Guillemin and colleagues at the Salk Institute — the first hypothalamic releasing hormone identified, which contributed to the Nobel Prize in Physiology or Medicine 1977 awarded to Guillemin and Schally.
- Has been used clinically as protirelin for pituitary-thyroid function testing; Drugs@FDA lists the US product Thyrel TRH (NDA 018087) as discontinued.
- Extensive research literature on cognitive, mood, arousal, and neuroprotective effects developed across the 1970s-2000s, establishing the compound's non-endocrine research applications.
- Early clinical evaluation for amyotrophic lateral sclerosis (ALS) in the 1980s, with mixed results that did not support further clinical development in that indication.
- Research applications continue in specialised cognitive, neuroprotection, and mood-modulation contexts, though the compound is not mainstream in the modern cognitive-peptide research programme.
Section 3
Mechanism of Action
- 1Direct agonism at TRH receptors — the receptor system that mediates both the primary thyroid-axis pharmacology (via pituitary TRH receptors) and the central cognitive and mood effects (via CNS TRH receptor populations).
- 2Central arousal-and-alertness effects via engagement of CNS TRH receptor populations in the brainstem and forebrain — the mechanism-of-action framework for the observed cognitive and arousal effects.
- 3Modulation of monoamine systems (dopamine, norepinephrine, serotonin) — reported effects on neurotransmitter turnover and release in preclinical models providing the mechanistic scaffold for the mood-relevance research applications.
- 4Neuroprotective effects in preclinical models — reduced neuronal death under ischaemic and excitotoxic challenge, providing the mechanistic basis for the ALS clinical-evaluation history and continued neuroprotection research applications.
- 5Anti-depressant effects reported in some research contexts, plausibly via the monoamine-modulation mechanism and central TRH receptor engagement rather than the primary thyroid-axis pathway.
- 6Effects on cholinergic system activity in some preclinical work, providing an additional angle for the observed cognitive endpoints via cholinergic-cognitive pathway modulation.
- 7Reported effects on respiratory drive and autonomic function via brainstem TRH receptor engagement, providing a physiologically-broad research application context.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Past clinical use as a diagnostic agent (protirelin) for pituitary-thyroid function testing.
- 2Documented cognitive, arousal, and mood-modulation effects across a substantial research literature.
- 3Distinctive endogenous-tripeptide research-tool niche providing mechanism-of-action angles unavailable to other peptides on this reference.
- 4Reported neuroprotective effects in preclinical models providing continued research application angles beyond the primary cognitive-endpoint research.
- 5Substantial acute-safety database from decades of diagnostic clinical use.
- 6Endogenous status providing a partial safety floor at physiological concentrations.
- 7Historical significance as the first hypothalamic releasing hormone identified.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration | Source |
|---|---|---|---|---|
| Intravenous (diagnostic use) | Diagnostic dose not stated on this profile (no cited source) | Single-dose for diagnostic testing; repeated doses in research applications | Diagnostic use is single-dose; research applications vary widely | None cited |
Note: Cognitive-endpoint research applications are entirely investigational and dose selection follows research-context conventions rather than licensed-indication protocols.
Section 6
Administration Routes
- Intravenous administration — the diagnostic route.
- Intranasal administration used in some research applications, exploiting nose-to-brain delivery for CNS-targeted effects.
- Subcutaneous administration in animal research contexts.
- Oral administration produces limited bioavailability owing to gastrointestinal proteolysis, though some sublingual and buccal formulations have been explored.
Section 7
Safety Profile
Commonly reported
- · Transient effects following IV administration — nausea, flushing, mild transient hypertension — the expected acute-response signals from the diagnostic clinical use.
- · Urgency of micturition following IV administration is a characteristic and expected effect.
- · Occasional metallic taste following IV administration.
- · Well-tolerated in the diagnostic clinical experience at studied doses.
Rare / theoretical
- · Rare hypersensitivity reactions.
- · Rare seizure precipitation in susceptible patients at higher doses.
- · Long-term chronic-use safety at cognitive-relevant research doses is limited to the ALS clinical-evaluation experience.
- · Theoretical thyroid-axis effects at chronic high doses despite the acute-administration diagnostic pharmacology.
Contraindications
- · No entry for protirelin or TRH was found in the electronic medicines compendium (emc) on 17 October 2026. Cognitive-endpoint use is investigational.
- · Uncontrolled thyroid disease.
- · Pregnancy — the diagnostic indication is generally deferred until after delivery unless clinically necessary.
- · Severe uncontrolled cardiovascular disease.
Section 8
UK & EU Regulatory Context
United Kingdom
No entry for protirelin or TRH was found in the electronic medicines compendium (emc) on 17 October 2026. Protirelin has been used as a diagnostic agent for pituitary-thyroid function testing (Wikipedia, Thyrotropin-releasing hormone); Drugs@FDA lists Thyrel TRH (protirelin injection, Ferring, NDA 018087) with marketing status Discontinued. Its cognitive-endpoint use is investigational.
European Union
Not on the EMA's list of centrally authorised medicines (checked 17 October 2026).
Section 9
Clinical Studies Summary
TRH cognitive and arousal effects — classical research characterisation
Extensive classical characterisation of TRH's cognitive and arousal effects across animal and human research contexts, establishing the compound's non-endocrine cognitive-and-arousal research applications and providing the mechanism-of-action scaffold for the mood and cognitive-relevance research angles.
TRH in amyotrophic lateral sclerosis (ALS) clinical evaluation
Early clinical evaluation of TRH in ALS patient populations reporting mixed results — some positive short-term functional improvements but no sustained clinical benefit sufficient to support further clinical development in the indication. Contributed to the historical neuroprotection research angle without producing definitive evidence.
TRH mood-modulation and antidepressant-like effects
Research characterising TRH's mood-modulation effects across animal and human depression research contexts, reporting antidepressant-like effects and providing the mood-relevance research application angle alongside the primary cognitive-endpoint research.
TRH mechanism — central receptor engagement and monoamine modulation
Molecular and behavioural pharmacology characterisation of TRH's central receptor engagement and downstream monoamine system modulation, providing the mechanistic scaffold for the observed cognitive, mood, and arousal effects that are separable from the primary thyroid-axis pharmacology.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing TRH (Thyrotropin-releasing hormone) for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain TRH (Thyrotropin-releasing hormone) from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: this page is educational. Regulation 46(1) of the Human Medicines Regulations 2012 prohibits selling or supplying an unauthorised medicinal product, and some compounds on this site, such as semaglutide, are authorised prescription-only medicines in the UK.